Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L‐745,870 and U‐101958 at human recombinant D4.4 receptors expressed in CHO cells
- 1 October 1999
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 128 (3) , 613-620
- https://doi.org/10.1038/sj.bjp.0702849
Abstract
1. The relationships between the density of dopamine D4.4 receptors and the agonist efficacies of L-745,870 (3-(4-[4-chlorophhenyl]piperazin-1-yl)-methyl-1H-pyrrolo [2, 3-b]pyridine) and U-101958 ((1-benzyl-piperidin-4-yl)-(3-isopropoxy-pyridin-2-yl)-methyl-a min e) were investigated in Chinese hamster ovary (CHO) cells, after treatment with the gene expression enhancer, sodium butyrate. 2. In CHO cells expressing D4.4 receptors (CHO/D4 cells), dopamine inhibited forskolin-stimulated cyclic AMP accumulation (Emax 56+/-1% inhibition, pEC50 7.4+/-0.1, n=10). U-101958 behaved as a partial agonist (39+/-7% the efficacy of dopamine, pEC50 8.1+/-0.3, n=4), whereas L-745,870 had no detectable agonist effect. 3. Receptor density, as estimated by [3H]-spiperone saturation binding was 240+/-30 fmol mg-1 protein (n=8) in CHO/D4 cell homogenates. It reached 560+/-150 (n=6), 1000+/-190 (n=4) and 840+/-120 (n=4) fmol mg-1 protein after treatment with sodium butyrate (5 mM) for 6, 18 and 48 h, respectively. 4. The increase in receptor density was associated with a gradual enhancement of the agonist effects (increased Emax and pEC50 values) of dopamine. The efficacy of U-101958 (relative to dopamine) doubled and L-745,870 was turned into a partial agonist (efficacy 49% relative to dopamine, pEC50 8. 6+/-0.2, n=6, after 48 h treatment with sodium butyrate). These agonist effects of U-101958 and L-745,870 could be antagonized by spiperone (0.1 microM) but not by raclopride (10 microM). 5. The results show that U-101958 and L-745,870 are partial agonists at human dopamine D4.4 receptors expressed in CHO cells. Their efficacy is governed by receptor density. Agonist effects of these two compounds in vivo cannot be excluded under circumstances of increased receptor levels.Keywords
This publication has 32 references indexed in Scilit:
- Effects of varying the expression level of recombinant human mGlu1α receptors on the pharmacological properties of agonists and antagonistsBritish Journal of Pharmacology, 1999
- Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1Band 5-HT1Dreceptors expressed in various mammalian cell linesBritish Journal of Pharmacology, 1998
- The Importance of Dopamine D4 Receptors in the Action and Development of Antipsychotic AgentsDrugs, 1996
- Deriving the therapeutic concentrations for clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligandEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Inducible expression of α1B-adrenoceptors in DDT1 MF-2 cells: comparison of receptor density and responseEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Dopamine D4 receptors elevated in schizophreniaNature, 1993
- High Level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells Using Glutamine Synthetase Gene AmplificationNature Biotechnology, 1990
- Multiple receptors for dopamineNature, 1979
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976